

High quality ion channel screening and drug discovery services

Metrion provide unparalleled expertise in **ion channel electrophysiology** and **validated screening assays** as part of our dedicated, flexible and cost-effective services tailored to customers' needs.


Contact us: info@metrionbiosciences.com



One of Metrion's key specialities is **cardiac safety screening**

- **Complete package of assays** to meet the FDA's Comprehensive *in vitro* Proarrhythmia assay (CiPA) program, designed to predict human clinical proarrhythmic risk
- **Full panel** of validated *in vitro* cardiac ion channel assays (incl. hERG, Nav1.5 & Cav1.2)
- **In silico modelling** of human action potentials
- Patch clamp and phenotypic assays using **human iPSC-derived cardiomyocytes**


Cardiac safety profiling



Panel of human cardiac ion channel assays, including hERG (manual and automated patch clamp)

[Learn more](#)


In silico modelling



High quality 'gigaseal' patch clamp data enables accurate *in silico* modelling of human action potentials

[Learn more](#)

iPS cardiomyocyte assays



Electrophysiology assays using human iPSC-derived cardiomyocytes can confirm *in silico* modelling findings

[Learn more](#)

Latest Publication

- Metrion Biosciences recently published a peer-reviewed paper describing use of the ND7-23 neuroblastoma cell line for high throughput native cell ion channel assays and neuroscience screening - [read more](#)

Recent News

- Axol Bioscience and Metrion Biosciences Announce iPS cell Research Collaboration – [read more](#)

Meet us

- The Safety Pharmacology Society meeting, Vancouver (18th-21st September 2016) – [read more](#)